Asia Mixed Amid U.S.-China Trade Truce
Asia-Pacific markets traded mixed Wednesday after the U.S.-China talks in Sweden ended without a tariff truce extension Tuesday stateside. A postponement of higher duties won’t be final until President Donald Trump signs off on the plan, U.S. negotiators said.
In Japan, the Nikkei 225 lost 19.85 points, or 0.1%, to 40,654.70.
In Hong Kong, the Hang Seng dumped 347.52 points, or 1.4%, to 25,176.93.
U.S. Commerce Secretary Howard Lutnick also affirmed that President Donald Trump’s upcoming Friday deadline to impose major tariffs on a slew of trading partners will not be delayed further.
However, Lutnick noted that trade negotiations with China are progressing on a separate timeline, as he told the media.
Europe’s largest lender HSBC on Wednesday missed second-quarter profit expectations, mostly on account of impairment charges, according to the bank. The bank also announced a share buyback of $3 billion.
It reported profit before tax for the three months ended June of $6.3 billion, down 29% from a year ago.
In other markets
In Shanghai, the CSI 300 let go of 0.78 points to 4,151.24.
In Korea, the Kospi index added 23.9 points, or 0.7%, to 3,254.47.
In Singapore, the Straits Times index dropped 10 points, or 0.2%, to 4,219.41.
In Taiwan, the Taiex index popped 260.2 points, or 1.1%, to 23,461.72.
In New Zealand, the NZX 50 ditched 80.44 points, or 0.6%, to 12,855.97.
In Australia, the ASX 200 gained 51.75 points, or 0.6%, to 8,756.37.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


